Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: a case report
| Autor: | Atsuya Horie, Yoshiharu Tokuyama, Azuma Kanatsuka, Toshiharu Ishizuka |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Type 1 diabetes business.industry Endocrinology Diabetes and Metabolism Fatty liver Case Report 030209 endocrinology & metabolism 030204 cardiovascular system & hematology medicine.disease 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Ipragliflozin Insulin resistance chemistry Diabetes mellitus Internal medicine Internal Medicine medicine Metabolic syndrome Cotransporter business Dyslipidemia |
| Zdroj: | Diabetol Int |
| ISSN: | 2190-1686 2190-1678 |
| DOI: | 10.1007/s13340-020-00448-4 |
| Popis: | We herein report the clinical course of a 56-year-old Japanese patient with slowly progressive type 1 diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver disease, and severe insulin resistance. The patient’s intravenous glucose tolerance test indicated marked reductions in insulin sensitivity and endogenous insulin secretion. Accordingly, administration of ipragliflozin l-proline, a sodium-glucose cotransporter 2 inhibitor, promoted improvements in insulin sensitivity and blood glucose levels, as well as a decrease in visceral fat, improvement in dyslipidemia, and decrease in hepatic lipid content, suggesting the potential efficacy of sodium-glucose cotransporter 2 inhibitors for obese patients with type 1 diabetes mellitus exhibiting insulin resistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink